Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 13:11:701-706.
doi: 10.2147/OPTH.S119926. eCollection 2017.

Meibomian gland dysfunction patients with novel Sjögren's syndrome biomarkers benefit significantly from a single vectored thermal pulsation procedure: a retrospective analysis

Alice T Epitropoulos  1   2 , Krysta Goslin  2 , Raman Bedi  3 , Caroline A Blackie  4
Affiliations

Meibomian gland dysfunction patients with novel Sjögren's syndrome biomarkers benefit significantly from a single vectored thermal pulsation procedure: a retrospective analysis

Alice T Epitropoulos et al. Clin Ophthalmol. .

Abstract

Purpose: To measure the effects from a single vectored thermal pulsation treatment of the meibomian glands on dry eye signs and symptoms in patients who tested positively versus negatively for novel Sjögren's syndrome (SS) biomarkers.

Methods: The retrospective study included the deidentified data of 102 eyes of 59 patients with dry eye and meibomian gland dysfunction (MGD), who were also tested for novel biomarkers for SS and underwent a single 12-minute LipiFlow thermal pulsation procedure. All patients were already being treated with individualized dry eye therapy but remained symptomatic. Meibomian gland secretion (MGS) scores, Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire scores and tear breakup times (TBUTs) before and 8 weeks after thermal pulsation treatment were analyzed.

Results: Twenty-three patients tested positive for novel biomarkers of SS and 36 patients tested negative. At baseline, MGS, SPEED and TBUT of both SS-positive and SS-negative patients were equivalent. At 8 weeks' post-treatment, mean MGS score, SPEED and TBUT were 13.0±7.8, 12.5±6.8 and 9.6±4.6, respectively, in SS-positive patients and 15.9±7.9, 10.0±6.3 and 8.3±4.6, respectively, in SS-negative patients (P<0.001). While the post-treatment MGS was significantly better in SS-negative patients than SS-positive (P=0.021), no significant difference between post-treatment SPEED and TBUT was observed between the two groups (P>0.05).

Conclusion: LipiFlow treatment in MGD patients who were SS-positive for novel biomarkers of SS demonstrated improvement in signs and symptoms of dry eye. While improvement in MGS scores in SS-negative patients was higher than that observed in SS-positive patients, SPEED and TBUT were equivalent between these two groups.

Keywords: LipiFlow; Sjögren’s syndrome; Sjögren’s syndrome with MGD; dry eye.

PubMed Disclaimer

Conflict of interest statement

Disclosure ATE and RB are consultants to TearScience. CAB is a TearScience employee. KG reports no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Effect of LipiFlow treatment on meibomian gland secretion (MGS) score of Sjögren’s syndrome (SS)-positive and SS-negative patients.
Figure 2
Figure 2
Effect of LipiFlow treatment on Standard Patient Evaluation of Eye Dryness (SPEED) score of Sjögren’s syndrome (SS)-positive and SS-negative patients.
Figure 3
Figure 3
Effect of LipiFlow treatment on tear breakup time (TBUT) of Sjögren’s syndrome (SS)-positive and SS-negative patients.
See this image and copyright information in PMC

References

    1. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop (2007) Ocul Surf. 2007;5(2):75–92. No authors listed. - PubMed
    1. Coursey TG, de Paiva CS. Managing Sjogren’s syndrome and non-Sjogren syndrome dry eye with anti-inflammatory therapy. Clin Ophthalmol. 2014;8:1447–1458. - PMC - PubMed
    1. Fox RI. Sjogren’s syndrome: current therapies remain inadequate for a common disease. Expert Opin Investig Drugs. 2000;9(9):2007–2016. - PubMed
    1. Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjogren’s syndrome. Clin Rev Allergy Immunol. 2007;32(3):284–291. - PubMed
    1. Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52(4):2050–2064. - PMC - PubMed

LinkOut - more resources